Literature DB >> 28529406

Implementing Optimal Allocation in Clinical Trials with Multiple Endpoints.

Lu Wang1, Yong Chen2, Hongjian Zhu1.   

Abstract

Modern clinical trials are often complex, with multiple competing objectives and multiple endpoints. Such trials should be both ethical and efficient. In this paper, we overcome the obstacles introduced by the large number of unknown parameters and the possible correlations between the multiple endpoints. We obtain the optimal allocation proportions for the following two optimization problems: (1) maximizing the power of the test of homogeneity with a fixed sample size, and (2) minimizing the expected weighted number of failures with a fixed power. Further, we implement these optimal allocations through response-adaptive randomization procedures. Our theoretical results provide the foundation for the implementation and further investigation of the procedure, and our numerical studies demonstrate its ability to achieve diverse objectives.

Entities:  

Keywords:  Clinical trial; Multiple endpoints; Optimal allocation; Power; Response-adaptive design

Year:  2016        PMID: 28529406      PMCID: PMC5435386          DOI: 10.1016/j.jspi.2016.09.002

Source DB:  PubMed          Journal:  J Stat Plan Inference        ISSN: 0378-3758            Impact factor:   1.111


  13 in total

1.  Optimal adaptive designs for binary response trials.

Authors:  W F Rosenberger; N Stallard; A Ivanova; C N Harper; M L Ricks
Journal:  Biometrics       Date:  2001-09       Impact factor: 2.571

2.  A comparison of urn designs for randomized clinical trials of K > 2 treatments.

Authors:  A Ivanova; W F Rosenberger
Journal:  J Biopharm Stat       Date:  2000-02       Impact factor: 1.051

3.  A graphical approach to sequentially rejective multiple test procedures.

Authors:  Frank Bretz; Willi Maurer; Werner Brannath; Martin Posch
Journal:  Stat Med       Date:  2009-02-15       Impact factor: 2.373

4.  Optimal response-adaptive designs for normal responses.

Authors:  Atanu Biswas; Rahul Bhattacharya
Journal:  Biom J       Date:  2009-02       Impact factor: 2.207

5.  The non-central chi2- and F-distributions and their applications.

Authors:  P B PATNAIK
Journal:  Biometrika       Date:  1949-06       Impact factor: 2.445

6.  Urokinase-streptokinase embolism trial. Phase 2 results. A cooperative study.

Authors: 
Journal:  JAMA       Date:  1974-09-16       Impact factor: 56.272

7.  Group sequential tests for bivariate response: interim analyses of clinical trials with both efficacy and safety endpoints.

Authors:  C Jennison; B W Turnbull
Journal:  Biometrics       Date:  1993-09       Impact factor: 2.571

8.  Effect of propranolol on myocardial-infarct size in a randomized blinded multicenter trial.

Authors:  R Roberts; C Croft; H K Gold; T D Hartwell; A S Jaffe; J E Muller; S M Mullin; C Parker; E R Passamani; W K Poole
Journal:  N Engl J Med       Date:  1984-07-26       Impact factor: 91.245

9.  Neutrophil elastase inhibition in acute lung injury: results of the STRIVE study.

Authors:  Bernhardt G Zeiher; Antonio Artigas; Jean-Louis Vincent; Alexei Dmitrienko; Kimberley Jackson; B Taylor Thompson; Gordon Bernard
Journal:  Crit Care Med       Date:  2004-08       Impact factor: 7.598

10.  Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Nocturnal Oxygen Therapy Trial Group.

Authors: 
Journal:  Ann Intern Med       Date:  1980-09       Impact factor: 25.391

View more
  1 in total

1.  Response adaptive randomization procedures in seamless phase II/III clinical trials.

Authors:  Hongjian Zhu; Jin Piao; J Jack Lee; Feifang Hu; Lixin Zhang
Journal:  J Biopharm Stat       Date:  2019-08-27       Impact factor: 1.051

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.